Receptor Binding Mechanisms
Receptor Binding Mechanisms - Related Videos
06:27
Competitive Binding Assay to Identify Compounds Disrupting Receptor-Ligand Interactions
0 Views •
2025
In this video, we describe a flow cytometry-based competitive binding assay to detect the interactions between the CXC Chemokine Receptor 4 (CXCR4) and its fluorescently-labeled natural ligand CXC Chemokine Ligand 12 (CXCL12), in the presence of a CXCR4-targeting small molecule. Incubating CXCR4-expressing cells with lower small molecule concentrations allows CXCR4-CXCL12 binding to some extent, which progressively declines upon a gradual increase in small molecule concentrations.
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
0 Views •
Cited by 11 •
2017
Guanosine triphosphate (GTP) binding is one of the earliest events in G-Protein-Coupled Receptor (GPCR) activation. This protocol describes how to pharmacologically characterize specific GPCR-ligand interactions by monitoring the binding of the radio-labeled GTP analog, [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPγS), in response to a ligand of interest.
08:40
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
0 Views •
Cited by 40 •
2016
The presented protocols describe two enzyme-linked immunosorbent assay (ELISA) based techniques for the rapid investigation of ligand-receptor interactions: The first assay allows the determination of dissociation constant between ligand and receptor. The second assay enables a rapid screening of blocking peptides for ligand-receptor interactions.
11:07
Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
0 Views •
Cited by 1 •
2011
An in vitro method for preparing functional glucocorticoid receptor (GR)•hsp90 protein complexes from purified proteins and cellular lysates is described. The method utilizes immunoadsorption of recombinant GR followed by salt-stripping and protein complex reconstitution. The importance of cofactors and buffer conditions are discussed, as are potential method applications.
01:16
Protein-Drug Binding: Mechanism and Kinetics
0 Views •
2025
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood. Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
FAQs
Molecular complementarity determines whether a ligand can fit and interact effectively with a receptor. Hydrogen bonding, electrostatic attraction, and hydrophobic interactions each contribute to recognition and stabilization of the ligand-receptor complex. Changes in these interactions can alter affinity, which helps explain why structurally related drugs may bind differently and produce unequal cellular effects.
Affinity describes how strongly a ligand interacts with a receptor, whereas receptor occupancy reflects how many receptors are bound at a given time. Together, these factors help shape the magnitude and duration of a response. A compound with strong affinity may maintain receptor engagement, while changing occupancy can modify treatment effects as ligand exposure changes.
Agonists bind in a way that activates the receptor and produces a cellular response. Antagonists occupy the receptor without permitting the intended activation, thereby preventing another ligand from producing its effect. Partial agonists generate an intermediate response, so their clinical impact may differ from both full activation and complete blockade when receptor interactions are evaluated.
Small differences between related compounds can change molecular complementarity and the balance of hydrogen bonding, electrostatic attraction, or hydrophobic interactions with a receptor. Those changes may alter affinity, occupancy, or the ability to activate or block the receptor. Consequently, compounds with similar structures can produce different therapeutic responses or adverse reactions in clinical research.
Drug discovery uses receptor-binding analysis to examine how candidate compounds recognize receptors, how strongly they interact, and whether they activate, block, or partially stimulate them. Comparing these properties helps researchers distinguish compounds with different expected responses. The findings can guide selection of candidates for further study and clarify why related molecules may behave differently.
Binding information helps connect ligand exposure with receptor occupancy and the resulting cellular response. In clinical research, this relationship can inform dose selection by indicating how much interaction may be associated with a desired effect. Monitoring these relationships also supports interpretation of treatment outcomes when response strength, duration, or adverse reactions differ among patients or compounds.